Former senator and Alston & Bird special counsel Bob Dole told The Wall Street Journal Monday that he and his firm helped arrange the president-elect’s taboo-breaking Friday telephone call with Taiwanese President Tsai Ing-wen. “It’s fair to say that we may have had some influence,” Dole told the paper.
- CFPB Takes Up Two New Fights to Force Subpoena Compliance
- Rejecting 'Newman,' SCOTUS Clears Up Rules for Insider-Trading Prosecutions
- In Latest Patent Case, Supreme Court Asks How Much Is Enough for Induced Infringement
- Apple Loses to Samsung in Supreme Court Design Patent Case
- Berkeley, MIT Clash Over Right to Profit From Gene-Editing Bonanza
- FDA Not Liable for $15 Million in Damages Sought by Produce Grower for Food Safety Warning Error
The U.S. Supreme Court on Tuesday handed a big win to whistleblowers, ruling that a violation of the federal False Claims Act's secrecy requirement doesn’t automatically mean a complaint should be dismissed. The unanimous ruling, delivered by Justice Anthony Kennedy, upheld a decision by the U.S. Court of Appeals for the Fifth Circuit.
After a lull in adding new cases to the term, the U.S. Supreme Court on Friday agreed to hear arguments in seven challenges, including a trio of cases from religious-affiliated, nonprofit health care systems that are seeking exemptions from federal law for their pension plans.
The Consumer Financial Protection Bureau is not letting up as the Obama administration winds down. In a span of three days last week, the agency went to federal courts in California and Michigan to force two financial-industry companies to cooperate with administrative subpoenas known as "civil investigative demands."
A national nonprofit advocacy group supporting legal access to medical marijuana has petitioned the U.S. Justice Department to require drug enforcers to correct allegedly false and misleading information about cannabis use on its website.
Calls For Nomination
Justice Stephen Breyer seemed persuaded on Tuesday that supplying a single component of a product for overseas assembly isn't enough to trigger extraterritorial application of U.S. patent laws.
With billions of dollars in licensing fees at stake, a panel of PTO judges seemed unlikely to hand either side a decisive win.